Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity

doi:10.3969/j.issn.1673-8640.2022.010.002

Abstract

Abstract:

Objective To investigate the changes of serum soluble leukocyte-associated immunoglobulin-like receptor-1（LAIR-1）（sLAIR-1） and LAIR-1 mRNA in peripheral blood mononuclear cells（PBMC） of patients with ankylosing spondylitis（AS） and their relationship with disease activity. Methods Totally，81 patients with AS were enrolled as AS group，and another 80 healthy subjects were enrolled as control group. The patients' clinical data and routine laboratory determination results were recorded. Serum sLAIR-1，interleukin（IL）-6 and IL-17 levels were determined，and the relative expression of LAIR-1 mRNA was determined as well. The difference between AS and control groups was compared. LAIR-1 and LAIR-1 mRNA levels were also determined in 17 patients with active AS of the 81 AS patients after 6 weeks of infliximab treatment. The correlations between sLAIR-1 and LAIR-1mRNA and the other indicators were analyzed by Spearman correlation analysis. Results Serum sLAIR-1，IL-17 and IL-6 in AS group were higher than those in control group（P<0.001），while LAIR-1 mRNA levels in AS group were lower（P<0.001）. Spearman correlation analysis showed that sLAIR-1 was positively correlated with IL-17，IL-6 and C-reactive protein（CRP）（r values were 0.482 4，0.475 3 and 0.391 6，respectively，P<0.01） and with the ankylosing spondylitis disease activity score（ASDAS） with CRP（ASDAS-CRP）（r value was 0.565 7，P<0.01），while LAIR-1 mRNA was negatively correlated with SLAIR-1， IL-17，IL-6，CRP and ASDAS-CRP（r values were -0.446 6，-0.399 6，-0.227 8，-0.265 1 and -0.366 8，respectively，P<0.05）. Serum sLAIR-1 was decreased（P<0.05），and LAIR-1 mRNA was increased（P<0.05） in patients with active AS after 6 weeks of infliximab treatment. Conclusions LAIR-1 was closely related to the disease activity，indicating that it may be used as a new indicator for the evaluation of AS disease activity.

Key words: Leukocyte-associated immunoglobulin-like receptor-1, Inflammatory cytokine, Peripheral blood mononuclear cell, Ankylosing spondylitis, Disease activity

HE Yaya, CHEN Shanshan, LI Yongsheng, LIU Juan. Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity[J]. Laboratory Medicine, 2022, 37(10): 915-920.

Figures/Tables 5

References 18

[1]	王静, 郑群, 金霞霞, 等. RDW与NLR联合检测在强直性脊柱炎中的临床意义[J]. 检验医学, 2019, 34(8):704-709.
[2]	CHEN L, AL-MOSSAWI M H, RIDLEY A, et al. MiR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis[J]. Ann Rheum Dis, 2017, 76(3):620-625. DOI URL
[3]	GUO N, ZHANG K, GAO X, et al. Role and mechanism of LAIR-1 in the development of autoimmune diseases,tumors,and malaria:a review[J]. Curr Res Transl Med, 2020, 68(3):119-124. DOI URL
[4]	BRAUN J, VAN DEN BERG R, BARALIAKOS X, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis[J]. Ann Rheum Dis,2011, 70(6):896-904. DOI URL
[5]	MACHADO P M, LANDEWÉ R, HEIJDE D V, et al. Ankylosing spondylitis disease activity score(ASDAS):2018 update of the nomenclature for disease activity states[J]. Ann Rheum Dis, 2018, 77(10):1539-1540. DOI URL
[6]	SCHNEEBERGER E E, ZAMORA N, CITERA G. SASDAS(simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis[J]. Clin Rheumatol, 2016, 35(11):2865-2866. DOI URL
[7]	JIN J, WANG Y, MA Q, et al. LAIR-1 activation inhibits inflammatory macrophage phenotype in vitro[J]. Cell Immunol, 2018, 331:78-84. DOI URL
[8]	JANSEN C A, CRUIJSEN C W, DE RUITER T, et al. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation[J]. Eur J Immunol, 2007, 37(4):914-924. PMID
[9]	SON M, DIAMOND B. C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1(LAIR-1)[J]. Mol Med, 2015, 20(1):559-568. DOI URL
[10]	MERLO A, TENCA C, FAIS F, et al. Inhibitory receptors CD85j,LAIR-1,and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes[J]. Clin Diagn Lab Immunol, 2005, 12(6):705-712.
[11]	SON M, SANTIAGO-SCHWARZ F, AL-ABED Y, et al. C1q limits dendritic cell differentiation and activation by engaging LAIR-1[J]. Proc Natl Acad Sci U S A, 2012, 109(46):E3160-E3167.
[12]	BONACCORSI I, CANTONI C, CARREGA P, et al. The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production[J]. PLoS One, 2010, 5(11):e15080.
[13]	OLDE NORDKAMP M J, VAN ROON J A, DOUWES M, et al. Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2(LAIR-2) and soluble LAIR-1 in rheumatoid arthritis:LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1[J]. Arthritis Rheum, 2011, 63(12):3749-3757. DOI URL
[14]	ZHANG Y, WANG S, DONG H, et al. LAIR-1 shedding from human fibroblast-like synoviocytes in rheumatoid arthritis following TNF-α stimulation[J]. Clin Exp Immunol, 2018, 192(2):193-205. DOI URL
[15]	KIM S, EASTERLING E R, PRICE L C, et al. The role of leukocyte-associated Ig-like receptor-1 in suppressing collagen-induced arthritis[J]. J Immunol, 2017, 199(8):2692-2700. DOI URL
[16]	OLDE NORDKAMP MJ, VAN ROON JA, DOUWES M, et al. Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2(LAIR-2) and soluble LAIR-1 in rheumatoid arthritis:LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1[J]. Arthritis Rheum, 2011, 63(12):3749-3757. DOI URL
[17]	GU Y, BI Y, WEI H, et al. Expression and clinical significance of inhibitory receptor leukocyte-associated immunoglobulin-like receptor-1 on peripheral blood T cells of chronic hepatitis B patients:a cross-sectional study[J]. Medicine(Baltimore), 2021, 100(29):e26667.
[18]	黄美玲, 李长钢, 王国兵, 等. 白细胞相关免疫球蛋白样受体-1在免疫性血小板减少症患儿中的表达[J]. 中国当代儿科杂志, 2014, 16(4):370-374.

基因	上游引物（5'~3'）	下游引物（5'~3'）	产物大小/bp
β-actin	TCCCATCACCATCTTCCAGG	GATGACCCTTTTGGCTCCC	145
LAIR-1	CGCCAGAATCAGATAAAGCAGG	CTGAGCATACGTCACCTCCT	198

基因	上游引物（5'~3'）	下游引物（5'~3'）	产物大小/bp
β-actin	TCCCATCACCATCTTCCAGG	GATGACCCTTTTGGCTCCC	145
LAIR-1	CGCCAGAATCAGATAAAGCAGG	CTGAGCATACGTCACCTCCT	198

组别	例数	吸烟史/%	BMI/（kg/m²）	WBC计数/（×10⁹/L）	LYMPH#/（×10⁹/L）
AS组	81	18（22.22）	23.25±2.95	8.13±1.98	2.72±0.85
正常对照组	80	17（21.25）	22.68±3.24	7.08±1.58	2.28±0.67
统计值		0.149	0.513	4.401	3.528
P值		0.803	0.681	0.005	0.013

组别	例数	吸烟史/%	BMI/（kg/m²）	WBC计数/（×10⁹/L）	LYMPH#/（×10⁹/L）
AS组	81	18（22.22）	23.25±2.95	8.13±1.98	2.72±0.85
正常对照组	80	17（21.25）	22.68±3.24	7.08±1.58	2.28±0.67
统计值		0.149	0.513	4.401	3.528
P值		0.803	0.681	0.005	0.013

组别	例数	sLAIR-1/（ng/mL）	LAIR-1 mRNA	IL-17/（pg/mL）	IL-6/（pg/mL）
AS组	81	5.17±2.37	0.54±0.46	11.37±4.15	22.17±9.13
正常对照组	80	1.72±1.17	1.79±1.12	4.99±1.92	8.08±3.59
统计值		11.680	9.290	12.440	13.010
P值		<0.001	<0.001	<0.001	<0.001